Phase I, Randomized, Parallel-group, Double-Blind, Placebo-Controlled, Single Dose Study to Evaluate the Blockade of CGRP Receptor by AMG 334 in Preventing PACAP-38 Induced Migraine-like Attacks in Migraine Patients
Phase of Trial: Phase I
Latest Information Update: 02 Jan 2018
At a glance
- Drugs Erenumab (Primary)
- Indications Migraine without aura
- Focus Therapeutic Use
- Sponsors Amgen
- 06 Dec 2017 Status changed from active, no longer recruiting to completed.
- 23 Oct 2017 Planned End Date changed from 9 May 2018 to 12 Nov 2017.
- 23 Oct 2017 Planned primary completion date changed from 9 May 2018 to 12 Nov 2017.